Dronedarone for atrial fibrillation: How does it compare with amiodarone?

■ ABSTRACT

Dronedarone (Multaq), an analogue of amiodarone (Cordarone), was designed to cause fewer adverse effects than the parent compound. Studies have indeed shown dronedarone to be safer than amiodarone, but less effective. Its official indication is to reduce the risk of hospitalization in patients with paroxysmal or persistent atrial fibrillation or atrial flutter and other cardiovascular risk factors, reflecting the parameters of its effectiveness in clinical trials.

■ KEY POINTS

Patients with persistent or paroxysmal atrial fibrillation are candidates for dronedarone therapy if they are in sinus rhythm or will be cardioverted soon after starting. This drug is not indicated for the acute management of atrial fibrillation, for example, in the emergency department.

Dronedarone is an option if a patient cannot tolerate amiodarone or has an underlying condition such as pulmonary or thyroid disease that is a contraindication to amiodarone.

Dronedarone is contraindicated in patients with significant left ventricular dysfunction or heart failure with recent decompensation.

The ultimate role for dronedarone is yet to be defined. Little evidence exists as to whether it will succeed when other drugs have failed.

Dronedarone (Multaq), approved by the US Food and Drug Administration in July 2009, is a congener of the antiarrhythmic drug amiodarone (Cordarone). Designed in the hope that it would be safer than amiodarone, its official indication is to lower the risk of hospitalization in patients with paroxysmal or persistent atrial fibrillation or atrial flutter. However, its precise role in the management of atrial fibrillation is yet to be defined. If dronedarone remains well tolerated, it may permit clinicians to pursue a rhythm control strategy more often. In this article, we present a progress report on this new agent.

Better antiarrhythmic drugs are needed

Atrial fibrillation increases the risk of stroke fivefold and accounts for 15% to 20% of all strokes. It also increases the risk of heart failure. Drugs are the mainstay of therapy, but many antiarrhythmic drugs are not very effective and cause cardiac and extracardiac toxicity. Thus, the need for safe and effective new drugs.

Much effort is going into the development of drugs that target specific ion channels or proteins expressed predominantly in atrial myocardium. The rationale is to avoid the unwanted effects of ionic currents on the ventricle and thus avoid ventricular proarrhythmic effects. At the same time, alternatives to the multiple channel blocker amiodarone, the mainstay of heart rhythm control therapy in atrial fibrillation, are being developed to retain the electrophysiologic efficacy of the mother compound but avoid its extracardiac toxicity.
RATE CONTROL VS RHYTHM CONTROL

In the acute care setting, heart rate control with atrioventricular nodal agents (beta-blockers, calcium channel blockers, and digitals) is the preferred initial strategy in most hemodynamically stable patients presenting with new-onset atrial fibrillation.3

Since we lack an effective method for maintaining sinus rhythm without incurring significant adverse effects, rate control is also often chosen for chronic management of atrial fibrillation. This is particularly true for patients who have no symptoms or only minimal symptoms and in whom adequate rate control is easily attained. Indeed, results of large clinical trials suggest that rate control is satisfactory for many patients.

The main purpose of rate control is to control symptoms as opposed to merely lowering the ventricular rate. Effective rate control often prevents hemodynamic instability in patients with underlying heart disease who present acutely with atrial fibrillation. In patients with permanent atrial fibrillation, the RACE II study4 (Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient Versus Strict Rate Control II), during a 3-year follow-up, showed that lenient rate control (resting heart rate < 110 beats per minute) is not inferior to strict rate control (resting heart rate < 80 beats per minute) in preventing major cardiovascular events (heart failure, stroke) or arrhythmic events such as syncope and sustained ventricular tachycardia.4

As a long-term strategy, rate control also prevents tachycardia-induced cardiomyopathy, reduces the risk of worsening of underlying heart failure, and can improve symptoms and quality of life.

Although maintenance of sinus rhythm is most likely associated with a survival benefit, heart rhythm control with antiarrhythmic drugs has not shown an advantage over rate control in overall or cardiovascular death rates, thromboembolic complications, or impact on heart failure. Indeed, a rhythm control strategy has been associated only with better exercise tolerance and, although less clear, with better quality of life.5

One possible explanation as to why a rhythm control strategy has not been shown to be superior to a rate control strategy is the side effects of the presently available drugs for rhythm control.

In a subgroup analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial,6 antiarrhythmic therapy was associated with a 49% increase in the mortality rate that offset the benefits of conversion and maintenance of sinus rhythm, which was associated with a 53% reduction in mortality rates.

The hope is that newer drugs with less toxicity may produce better outcomes for patients treated with rhythm control.

AN ANALOGUE OF AMIODARONE, WITHOUT THE IODINE

Dronedarone is a structurally modified version of amiodarone, the antiarrhythmic drug that has shown the greatest efficacy at maintaining sinus rhythm in patients with paroxysmal atrial fibrillation. Although historically amiodarone has been effective in maintaining sinus rhythm and has been used safely in patients with advanced heart failure, its use has been limited by cumulative and often irreversible extracardiac organ toxicity.

Dronedarone was designed to match amiodarone's efficacy but with a better safety profile. An iodine radical makes up more than one-third of amiodarone's molecular weight. The omission of iodine in dronedarone was intended to reduce the likelihood of toxic side effects.

Dronedarone is a benzofuran derivative pharmacologically related to amiodarone, with the addition of a methylsulfonamide group. This reduces lipophilicity and the propensity to cross the blood-brain barrier; over a 2-year period this drug has not been shown to have neurotoxic effects.7

Dronedarone has proved efficacious without toxic or proarrhythmic effects and has minimal side effects, but concerns remain regarding its use in advanced heart failure. To date, its adverse-event profile appears comparable to that of placebo. However, whether its efficacy and incidence of adverse effects are comparable to what has been reported in the literature may take time to assess.
Dronedarone’s Pharmacology

Dronedarone, like amiodarone, blocks multiple sodium and potassium ion channels. It also exerts an antiadrenergic effect by non-competitive binding to beta-adrenergic receptors as well as by inhibiting an agonist-induced increase in adenylate cyclase activity.

Compared with amiodarone, dronedarone is a more potent blocker of peak sodium current.

Dronedarone is largely metabolized by the hepatic enzyme cytochrome P450 3A4 isoform (CYP3A4). Only 6% of dronedarone is excreted renally; however, no trial has yet assessed dronedarone’s safety in patients with marked kidney dysfunction.

Dronedarone’s steady-state terminal elimination half-life is approximately 30 hours. When taken twice a day, it achieves steady-state concentrations in 5 to 7 days.

Dronedarone is available only for oral administration at 400 mg twice daily. Dose adjustment or titration is not recommended.

Clinical Trials of Dronedarone

Dronedarone vs placebo

ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death From any Cause in Patients With Atrial Fibrillation/Flutter) was a prospective, double-blind study to assess morbidity and death rates in 4,628 patients with atrial fibrillation or atrial flutter and at least one other cardiovascular risk factor.

ATHENA showed that dronedarone, in addition to standard therapy, significantly reduced the risk of a first cardiovascular hospitalization or death by 24% in patients with atrial fibrillation or atrial flutter at least one other cardiovascular risk factor.

EURIDIS and ADONIS. Two trials, EURIDIS (European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm) and ADONIS (American-Australian Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm), enrolled a total of more than 1,200 patients and showed that dronedarone 400 mg twice a day produced a significantly lower rate of recurrence of atrial fibrillation after electrical cardioversion compared with placebo.

Overall, treatment with dronedarone significantly reduced the risk of a first recurrence of atrial fibrillation by 22% (ADONIS) and 27.5% (EURIDIS) (Table 1).

ERATO (Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation), an additional phase III study, showed that dronedarone controlled the heart rate in patients with persistently accelerated ventricular rates despite concomitant standard therapy with a beta-blocker, digoxin, or a calcium-channel blocker. Dronedarone reduced the mean 24-hour heart rate by 11.7 beats per minute and the maximal exercise ventricular rate by 24.5 beats per minute at the 14th day.

ANDROMEDA (Anti-arrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease) was a study not of patients with atrial fibrillation but rather of patients with symptomatic congestive heart failure, a left ventricular ejection fraction of 35% or less, and recent hospitalization with new or worsening heart failure. The study was terminated early because of a higher rate of death with dronedarone (Table 1).

Dronedarone’s efficacy and safety are yet to be defined in those who have undergone coronary artery bypass surgery or have marked LV hypertrophy.
Dronedarone is indicated in persistent or paroxysmal atrial fibrillation, based on the observed reduction of the rate of hospitalization. It is indicated for the maintenance of sinus rhythm and may be used in patients with persistent or paroxysmal atrial fibrillation and flutter who are in sinus rhythm or will be undergoing cardioversion soon after starting the drug. Dronedarone has no role in the acute

### WHERE DOES DRONEDARONE FIT IN ATRIAL FIBRILLATION MANAGEMENT?

Dronedarone is indicated in persistent or paroxysmal atrial fibrillation, based on the observed reduction of the rate of hospitalization. It is indicated for the maintenance of sinus rhythm and may be used in patients with persistent or paroxysmal atrial fibrillation and flutter who are in sinus rhythm or will be undergoing cardioversion soon after starting the drug. Dronedarone has no role in the acute

### TABLE 1

**Clinical trials of dronedarone**

<table>
<thead>
<tr>
<th>STUDY</th>
<th>INCLUSION CRITERIA</th>
<th>EXCLUSION CRITERIA</th>
<th>TREATMENT AND FOLLOW-UP</th>
<th>EFFECTS ON PRIMARY ENDO POINTS</th>
<th>EFFECTS ON SECONDARY ENDO POINTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATHENA 10</td>
<td>Paroxysmal or persistent AF or atrial flutter, plus age &gt; 75 or age &gt; 70 and more than one other risk factor (hypertension, diabetes, stroke or transient ischemic attack, left atrium &gt; 50 mm or left ventricular ejection fraction &lt; 40%)</td>
<td>Permanent AF unstable hemodynamic status NYHA class IV heart failure</td>
<td>Dronedarone 400 mg twice daily for 12 months vs placebo</td>
<td>Death from all causes or first hospitalization for a cardiovascular event: 24.2% RR reduction, HR 0.76</td>
<td>Death from any cause: 16% fewer deaths with dronedarone Death from cardiovascular event: 29% RR reduction Hospitalization for cardiovascular event: 26% RR reduction Incidence of stroke: 34% RR reduction Length of hospitalization reduced by 1.26 days/patient/year</td>
</tr>
<tr>
<td>EURIDIS and ADONIS 11</td>
<td>Paroxysmal AF</td>
<td>Permanent AF CHF (NYHA class III or IV) Renal insufficiency</td>
<td>Dronedarone 400 mg twice daily for 12 months vs placebo</td>
<td>Time to AF recurrence: Dronedarone 116 days Placebo 53 days Recurrence rate: Dronedarone 64.1% Placebo 75.2%</td>
<td>Ventricular rate during AF recurrence: Dronedarone 103.4 ± 25.9 Placebo 117.1 ± 30.4 Symptomatic AF recurrence: Dronedarone 37.7% Placebo 46% Hospitalization or death: Dronedarone 22.8% Placebo 30.9%</td>
</tr>
<tr>
<td>ANDROMEDA 13</td>
<td>NYHA class III or IV heart failure, or paroxysmal nocturnal dyspnea and left ventricular ejection fraction &lt; 35%</td>
<td>Recent acute MI Acute pulmonary edema</td>
<td>Dronedarone 400 mg twice daily for 12 months vs placebo</td>
<td>Death from any cause or hospitalization from worsening heart failure: Dronedarone 17.1% Placebo 12.6%</td>
<td>Death from all causes: Dronedarone 8.1% Placebo 3.8% (HR 2.13) Hospitalization for cardiovascular event: Dronedarone 22.9% Placebo 15.7%</td>
</tr>
<tr>
<td>DIONYSOS 14</td>
<td>Persistent AF</td>
<td>Not yet reported</td>
<td>Dronedarone 400 mg twice daily vs amiodarone 600 mg/day for 28 days, followed by 200 mg daily for 6 months</td>
<td>AF recurrence or premature drug discontinuation for intolerance or lack of efficacy: Dronedarone 73.9% Amiodarone 55.3%</td>
<td>Main safety end point: 20% decrease favoring dronedarone Main safety end point excluding gastrointestinal effects: 39% decrease favoring dronedarone</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; CHF = congestive heart failure; NYHA = New York Heart Association; MI = myocardial infarction; HR = hazard ratio; RR = relative risk
management of atrial fibrillation, such as in cardioversion to sinus rhythm in the emergency department.

We do not have substantial evidence of the efficacy of dronedarone in patients with resistant atrial fibrillation, in whom multiple antiarrhythmics have failed to maintain sinus rhythm, and no published trial has used the inclusion criterion of treatment failure with other antiarrhythmic drugs.

The role of dronedarone in heart failure with preserved systolic function is unclear. Patients taking dronedarone are twice as likely as those taking amiodarone to have a recurrence of atrial fibrillation.

The main advantage of dronedarone is its lower adverse effect profile. However, this statement is based on only a few years of observation. If the patient has developed adverse effects with amiodarone, or if the clinician is concerned about the risk of serious adverse effects, dronedarone presents an alternative for those patients without heart failure or significant left ventricular dysfunction. One such group may be younger patients, because of concerns about the cumulative effects of amiodarone taken over a lifetime.

Dronedarone may represent an acceptable alternative to many of the current antiarrhythmic drugs. Based on the results of the Cardiac Arrhythmia Suppression Trial (CAST),15 class IC antiarrhythmics such as flecainide (Tambocor) are generally avoided in patients with prior myocardial infarction or with known or even suspected coronary artery disease. Similarly, sotalol (Betapace) is generally avoided in patients with marked left ventricular hypertrophy because of adverse effects.16 Dofetilide (Tikosyn) and often sotalol require hospitalization with telemetric monitoring for QTc prolongation and the risk of proarrhythmia with torsades de pointes. Dronedarone, however, generally can be safely started in the outpatient setting.

As when considering prescribing any antiarrhythmic, the clinician must assess the patient’s thromboembolic risk, since this risk persists with a rhythm control strategy.

There is substantial evidence from the ATHENA trial,10 in which 30% of the patients had coronary artery disease, that dronedarone is safe and effective in patients with coronary artery disease. Its use in patients who have undergone coronary artery bypass surgery remains to be defined.

■ WHEN SHOULD WE SWITCH PATIENTS TO DRONEDARONE?

Preliminary experience suggests that dronedarone, unlike most antiarrhythmic drugs, can be safely started about 48 hours after amiodarone is discontinued. Cumulative toxicity has not been noted with dronedarone. Caution should be exercised when switching if the patient has baseline bradycardia or QT interval prolongation. No algorithm has been developed for switching from other antiarrhythmic drugs to dronedarone.

■ CONTRAINDICATIONS TO DRONEDARONE

Dronedarone is contraindicated in:

- Patients with New York Heart Association (NYHA) class IV heart failure or NYHA class II or III heart failure with recent decompensation requiring hospitalization or referral to a specialized heart failure clinic
- Patients with second- or third-degree atrioventricular block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker) or bradycardia (a heart rate < 50 beats per minute)
- Patients with a QTc interval of 500 ms or longer
- Patients with severe hepatic impairment
- Women who are pregnant, are attempting to become pregnant, or are breast-feeding
- Patients taking potent CYP3A inhibitors—antifungals like ketoconazole (Nizoral),itraconazole (Sporanox), or voriconazole (VFEND); macrolide antibiotics like telithromycin (Ketek) or clarithromycin (Biaxin); protease inhibitors; or other drugs that prolong the QT interval.

In patients with new or worsening heart failure, one should consider suspending or stopping dronedarone therapy.

■ DRONEDARONE’S ADVERSE EFFECTS

In trials to date, dronedarone has not shown evidence of proarrhythmia (tachyarrhythmia or bradyarrhythmia), torsades de pointes,
or amiodarone-like organ toxicity affecting the thyroid or the lungs. Recently, rare cases of severe hepatic injury were associated with dronedarone; therefore, periodic liver function testing is advised for patients taking dronedarone, especially during the first 6 months of therapy.

Dronedarone has been associated with higher rates of diarrhea, nausea, bradycardia, QT interval prolongation, and cutaneous rash compared with placebo. In DAFNE (Dronedarone Atrial Fibrillation Study After Electrical Cardioversion), 17% of patients taking dronedarone had to stop taking it because of adverse events. With 800 mg daily, the discontinuation rate was only 3.9%. The most common cause of drug discontinuation was gastrointestinal effects. Anecdotal reports suggest that the gastrointestinal side effects may be self-limited and may not always require discontinuation of the drug.

Serum creatinine levels increase by about 0.1 mg/dL after the start of treatment. This elevation occurs after 1 to 2 days, reaches a plateau after 7 days, and is reversible. The mechanism is thought to be that dronedarone partially inhibits tubular organic cation transporters, which in turn reduces renal creatinine clearance by about 18%, but with no evidence of an effect on glomerular filtration, renal plasma flow, or electrolyte exchanges. A limited increase in serum creatinine is, therefore, expected with dronedarone treatment, but this does not mean there is a decline in renal function.

■ DRONEDARONE AND POTENTIAL DRUG INTERACTIONS

**Warfarin.** Dronedarone does not increase the international normalized ratio when used with warfarin (Coumadin).

**Verapamil, diltiazem.** Dose reduction is required to avoid bradyarrhythmias with coadministration of moderate CYP3A4 inhibitors such as verapamil (Calan, Verelan) and diltiazem (Cardizem).

**Simvastatin.** Dronedarone increases levels of simvastatin (Zocor), a CYP3A4 substrate, two to four times, thus increasing the risk of statin-induced myopathy.

**Digoxin.** Dronedarone increases the serum digoxin concentration about 2.5 times, and this necessitates monitoring the digoxin level and possibly reducing the digoxin dose.

**Diuretics.** Hypokalemia and hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. Potassium levels should be maintained in the normal range before and during administration of dronedarone.

**Tacrolimus, sirolimus.** Dronedarone may increase levels of tacrolimus (Prograf) or sirolimus (Rapamune) in posttransplantation patients. This requires dose monitoring and adjustment in concomitant therapy with these agents.

■ COST VARIES

The cost of dronedarone varies based on factors that include location. Dronedarone’s retail cost ranges from $3.20 to $4.00 per pill (approximately $7.20 per day). It is not available in generic form. It is presently covered by many health plans as a tier 2 drug, representing a $15 to $40 monthly copay.

■ MORE DATA NEEDED

Dronedarone represents the first in what may well be a number of new antiarrhythmic drugs for the treatment of patients with paroxysmal atrial fibrillation. Although less efficacious than amiodarone, dronedarone appears to be better tolerated and have less serious side effects. It is contraindicated in patients with severe systolic dysfunction and in those with recent heart failure decompensation. It appears safe in coronary artery disease and marked left ventricular hypertrophy, unlike flecainide, propafenone (Rythmol), and sotalol.

To further understand how dronedarone will fare against other antiarrhythmic drugs, more studies with longer follow-up are needed. These studies need to demonstrate superior tolerability of dronedarone, acceptable quality of life without unacceptable loss of efficacy, or a decrease in morbidity or mortality rates compared with amiodarone.

Dronedarone can be safely started in most patients on an outpatient basis. The risk of proarrhythmia with dronedarone appears to be very low.
REFERENCES


ADDRESS: Neelima Penugonda, MD, Department of Internal Medicine, Lankenau Hospital, 100 East Lancaster Avenue, 3SW, Wynnewood, PA 19096; e-mail pneelu@gmail.com.